Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN

Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN

This is a prospective, randomized study. The purpose of this study is to evaluate if the addition of Suzetrigine, a new pain medication, to well established peri-operative pain regimen used for total knee replacement surgery will effect pain control.

1. Does Suzetrigine given pre-operatively decrease the total opioid consumed after total knee replacement surgery?
2. Dose Suzetrigine given pre-operatively decrease the visual analog pain scale pain scores after total knee replacement surgery? Study participants will be randomly assigned to receive either Suzetrigine medication or placebo medication.

Inclusion Criteria:

To be eligible to participate in this study, an individual must meet all of the following criteria:

• Adults 18-85 years old
• Scheduled to undergo total knee replacement surgery
• All genders

Exclusion Criteria:

Any individual who meets any of the following criteria will be excluded from participation in this study:

• American Society of Anesthesiology Physical Classification (ASA) Class V

• Urgent or emergent surgery

• Contraindications to administration of Suzetrigine:

  • Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and Clarithromycin)
  • Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)
  • Patients with moderate to severe hepatic impairment

• History of substance use disorder or chronic opioid use or alcohol abuse

• Reoperation

• Patient refusal or inability to consent

• Pregnancy